Abbott Laboratories News

On Wednesday and Thursday, The Deal was in conference mode, hosting panels of high-profile dealmakers on financial and corporate sides, doing post-panel video interviews and live-blogging. The two-day Deal Economy 2010 event was capped off in a packed room where strategic dealmakers received honors for their M&A work .

Six months after the California Supreme Court lowered standing requirements for consumer class actions, a state trial judge has certified a class of consumers who purchased contact lens solution linked to an infection that can cause blindness.

Nov. 23, 2009 -- A new study of the weight loss drug Meridia is in the hands of FDA regulators, who've released an early communication based on preliminary data: certain patients taking the drug may have a higher risk of heart attacks , strokes, and other serious cardiovascular problems.

Abbott Laboratories sued Teva Pharmaceutical Industries Ltd., the world's largest generic-drug maker, to prevent it from marketing copies of the Zemplar kidney-disease treatment.

Abbott and BG Medicine, Inc. announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure.

US REGULATORS are reviewing preliminary data suggesting patients taking Abbott Laboratories Inc's weight loss drug Meridia may have a higher risk of cardiovascular problems, the Food and Drug Administration said on Friday.

There is nearly universal agreement that reform of the U.S. patent system is urgently needed.

Annis Fuller thought she had everything in place to retire this past June. But when the Abbott Laboratories accountant and her husband, who manages construction projects for the company, met with their financial planner last December, the news wasn't good.

A UBS analyst said Wednesday that medical technology stocks are trading at attractive prices, and raised his ratings or price targets on nine of them.

Former presidents Bill Clinton and George W. Bush are used to playing for different teams.

Abbott today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries.

Somewhere in Chicago right now, there's a salesman in a company SUV, idling the engine while he makes calls in a restaurant parking lot.

A finding that Merck & Co.a s cholesterol pills Vytorin and Zetia didna t reopen clogged arteries as well as Abbott Laboratories a Niaspan has set off a medical debate on heart treatment strategies.

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor , today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic.

The growth of the Chinese economy has brought opportunities for multinational companies and has a great future, according to a senior executive from U.S. health care company Abbott Laboratories.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/12/09, Abbott announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor , expanding the company's pain care portfolio and leveraging its expertise in biologics.

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor , expanding the company's pain care portfolio and leveraging its expertise in biologics.

The Houston trial law firm Arnold & Itkin LLP has filed five lawsuits against the makers of pain pumps and related medications based on claims that many of the companies' defective devices are causing irreversible shoulder damage among patients.

Filed under: Market matters , Abbott Laboratories , Aetna Inc , CIGNA Corp , Gilead Sciences , Stocks to Buy , Cramer on BloggingStocks TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge.

He's up 1,334%! See what David's recommending that you buy NEXT! Click here now to find out! At least so far, 2009 has been a welcome relief from the pain that 2008 inflicted on most investors.